Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
NCT03308825
Completed
The aim of the study was to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone Quadrivalent vaccine in children 6 months to \< 9 years of age, and in adults 18 to \< 65 years of age, and to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone High-Dose vaccine in adults ≥ 65 years of age.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
03/15/2022
Locations: Sanofi Pasteur Investigational Site 003, Council Bluffs, Iowa +2 locations
Conditions: Influenza, Flu
Register for Updates
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
NCT03617523
Completed
The primary objectives of this study were: * To describe the immunogenicity of the 2018-2019 formulation of Fluzone® Quadrivalent vaccine in children 6 to less than (\<) 36 months of age and 3 to \<9 years of age, and in adults 18 to \<65 years of age; the immunogenicity of the 2018-2019 formulation of Flublok® Quadrivalent vaccine in adults 18 to \<65 years of age; and the immunogenicity of the 2018-2019 formulation of Fluzone High-Dose vaccine in adults greater than or equal to (\>=) 65 years... Read More
Gender:
ALL
Ages:
6 months and above
Trial Updated:
03/15/2022
Locations: Investigational Site Number 8400003, Bardstown, Kentucky +2 locations
Conditions: Influenza
Register for Updates
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
NCT02587520
Completed
This was a dose and formulation ranging study to assess the safety and immunogenicity of SP0173 in healthy adolescents, adults, and older adults in the United States (US). Primary Objective * To describe the safety profile of each SP0173 investigational formulation. Observational Objective: * To describe the immunogenicity of each SP0173 investigational formulation.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
03/15/2022
Locations: Not set, Birmingham, Alabama +19 locations
Conditions: Tetanus, Diphtheria, Pertussis, Whooping Cough
Register for Updates
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
NCT01488890
Completed
The aim of this study was to evaluate the administration of CYD dengue vaccine serotypes (1, 2, 3 and 4) following a compressed schedule in 3 different populations. Primary Objectives: * To describe the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after CYD dengue vaccine Dose 3 in Group 1 (Month \[M\] 13) and Group 2 (M07), irrespective of whether or not Yellow Fever (YF) vaccine has been previously administered. * To describe the persistenc... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/15/2022
Locations: Not set, Alabaster, Alabama +6 locations
Conditions: Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
Register for Updates
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
NCT01061840
Completed
Autologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid. The GMCSF protein is a potent stimulator of the immune system, recruiting immune effectors to the site of intradermal injection and promoting antigen presentation. The furin bifunctional shRNA blocks furin protein production at the post transcriptional and translational levels. This decrease in furin in turn decreases the conversion of the proforms TGFβ1 and TGFβ2 proteins. Also, reduced furin protein levels h... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/14/2022
Locations: Florida Cancer Specialists, West Palm Beach, Florida +3 locations
Conditions: Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
Register for Updates
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
NCT02362451
Terminated
Background: - Men who continue to have an elevated or rising prostate specific antigen (PSA) level after their primary prostate cancer treatment are at increased risk for their cancer to progress. The time it takes to progress is highly variable. One way to predict this progression is based on the change in PSA levels over time. This is called the PSA doubling time (PSADT). Researchers want to test a vaccine on men with Stage D0 prostate cancer. Stage D0 means the PSA has become detectable agai... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/10/2022
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Prostatic Neoplasms, Prostate Cancer
Register for Updates
Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
NCT03954743
Completed
The purpose of this study is to complete the total safety database size for GlaxoSmithKline Biologicals' (GSK's) human rotavirus (HRV) vaccine across the Porcine circovirus (PCV)-free development plan. This study used a purposely selected lot for PCV-free liquid HRV vaccine that is in the upper range of the usual release potencies. The PCV-free liquid HRV vaccine lots used were stored frozen in order to keep the titer stable until administration during the study. As the liquid formulation of G... Read More
Gender:
ALL
Ages:
Between 6 weeks and 12 weeks
Trial Updated:
02/25/2022
Locations: GSK Investigational Site, Birmingham, Alabama +36 locations
Conditions: Infections, Rotavirus
Register for Updates
Safety and Immunogenicity of a Hantaan Virus DNA Vaccine and a Puumala Virus DNA Vaccine, For The Prevention of Hemorrhagic Fever With Renal Syndrome
NCT04333459
Unknown
A randomized 4 cohort study that is comparing the data collected during the earlier phase study and to determine if immunogenicity can be retained with a 1 mg dose of Hantaan DNA vaccine.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/16/2022
Locations: Clinical Trials Center, Walter Reed Army Institute of Reserach, Silver Spring, Maryland
Conditions: Hantaan Virus Nephropathy, Puumala Virus Nephropathy
Register for Updates
Novelty, Conformity and Trust in COVID-19 Vaccines
NCT04693689
Completed
Despite their established benefits as public measures, vaccines continue to be treated with suspicion by many people, in the US and other parts of the world (Larson et al. 2014; Olive et al. 2018; Lazarus et al. 2020). Since the success of vaccines depends on their high uptake level (Anderson and May, 1985; Fine et al. 2011; Fontanet and Cauchemez, 2020), identifying factors that influence low trust and decision-making in relation to vaccines is essential in order to combat diseases such as the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2022
Locations: SurveyMonkey, San Mateo, California
Conditions: Trust
Register for Updates
Umbilical Cord Blood Infusion to Treat Type 1 Diabetes
NCT00305344
Completed
While this study is now completely enrolled, we do hope to develop a "next generation" cord blood based study sometime in early 2009. Please continue to contact us if you have a child with newly diagnosed Type 1 Diabetes (T1D) who alo has their OWN cord blood in storage.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
02/03/2022
Locations: University of Florida, Gainesville, Florida
Conditions: Type 1 Diabetes Mellitus
Register for Updates
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
NCT02737475
Completed
The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/25/2021
Locations: University Of Colorado, Aurora, Colorado +21 locations
Conditions: Advanced Cancer
Register for Updates
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
NCT02787044
Completed
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2021
Locations: Birmingham VAMC, Birmingham, Alabama +189 locations
Conditions: Heart Failure, Myocardial Infarction
Register for Updates